Inflammation in cystic fibrosis: An update
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Inflammation plays a critical role in cystic fibrosis (CF) lung pathology and disease progression making it an active area of research and important therapeutic target. In this review, we explore the most recent research on the major contributors to the exuberant inflammatory response seen in CF as well as potential therapeutics to combat this response. Absence of functional cystic fibrosis transmembrane conductance regulator (CFTR) alters anion transport across CF airway epithelial cells and ultimately results in dehydration of the airway surface liquid. The dehydrated airway surface liquid in combination with abnormal mucin secretion contributes to airway obstruction and subsequent infection that may serve as a trigger point for inflammation. There is also evidence to suggest that airway inflammation may be excessive and sustained relative to the infectious stimuli. Studies have shown dysregulation of both pro‐inflammatory mediators such as IL‐17 and pro‐resolution mediators including metabolites of the eicosanoid pathway. Recently, CFTR potentiators and correctors have garnered much attention in the CF community. Although these modulators address the underlying defect in CF, their impact on downstream consequences such as inflammation are not known. Here, we review pre‐clinical and clinical data on the impact of CFTR modulators on inflammation. In addition, we examine other cell types including neutrophils, macrophages, and T‐lymphocytes that express CFTR and contribute to the CF inflammatory response. Finally, we address challenges in developing anti‐inflammatory therapies and highlight some of the most promising anti‐inflammatory drugs under development for CF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., Coquillette, S., Fieberg, A. Y., Accurso, F. J., Campbell III, P. W., et al. (2003) · JAMA · doi:10.1001/jama.290.13.1749 · Cited by 958 · cited 1×
“P aeruginosa infected and non-infected subject populations resulted in significant reductions in the risk of acute pulmonary exacerbation.(165,168) In those subjects infected with P aeruginosa, there was also a significant increase in lung function based on FEV1.”
BackgroundCaceres, S. M., Malcolm, K. C., Taylor-Cousar, J. L., Nichols, D. P., Saavedra, M. T., Bratton, D. L., Moskowitz, S. M., Burns, J. L., & Nick, J. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03514-14 · Cited by 50
Self-citation
Cited by
Neutrophils and NETS in modulating acute and chronic inflammation
Castanheira, F. V. S., & Kubes, P. (2019) · Blood · doi:10.1182/blood-2018-11-844530 · Cited by 792
Cystic fibrosis – Ten promising therapeutic approaches in the current era of care
Somayaji, R., Nichols, D. P., & Bell, S. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1805733 · Cited by 12
Self-citation
Metadata
- Authors
- Roesch, E. A., Nichols, D. P., & Chmiel, J. F.
- Venue
- Pediatric Pulmonology
- Publisher
- Wiley
- Published
- 2018-07-12
- Volume
- 53
- Issue
- S3
- Pages
- S30-S50
- ISSN
- 1099-0496 (ISSN-L)
- 8755-6863
- OpenAlex
- W2880439530
- Cited by
- 242
- References
- 2
- FWCI
- 18.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.